E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Study in the healthy population. This is a study of a test used in the diagnosis of the condition, Brugada Syndrome. |
|
E.1.1.1 | Medical condition in easily understood language |
Brugada Syndrome is a condition which can cause serious heart rhythm disturbances. Those affected by the condition can appear well and without symptoms before suffering from a sudden cardiac event. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003109 |
E.1.2 | Term | Arrest cardiac |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003119 |
E.1.2 | Term | Arrhythmia |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10059027 |
E.1.2 | Term | Brugada syndrome |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042436 |
E.1.2 | Term | Sudden death unexplained |
E.1.2 | System Organ Class | 100000004867 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10069779 |
E.1.2 | Term | Brugada-type ECG |
E.1.2 | System Organ Class | 100000004848 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008396 |
E.1.2 | Term | Change in ECG |
E.1.2 | System Organ Class | 100000004848 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to examine the effects of Ajmaline, (which is the drug used to unmask Brugada syndrome), on healthy subjects.
|
|
E.2.2 | Secondary objectives of the trial |
To investigate whether the various electrocardiographic responses observed with an Ajmaline challenge are related to variations in genetic messages in healthy subjects. This is determined by anonymous genetic testing via blood sampling.
To investigate whether the various electrocardiographic responses observed with an Ajmaline challenge are related to variations in cardiac structure in healthy subjects. This is determined by non-invasive cardiac magnetic resonance imaging.
To investigate whether the various electrocardiographic responses observed with an Ajmaline challenge are comparable to those seen in the clinical setting in patients being investigated for Brugada Syndrome. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Asymptomatic healthy individuals Caucasian Aged 18-65 Kidney function ≥ 30ml/min/1.73m2 |
|
E.4 | Principal exclusion criteria |
Any prior cardiovascular illness Previous cardiac symptoms. History of unexplained syncope Any family history of proven sudden cardiac death or unexplained sudden death either in adulthood or infancy. Those unable to provide a two generation family history Abnormal resting ECG Abnormal screening cardiac ultrasound Any contraindications to cardiac magnetic resonance imaging participant has cardiac pacemaker; recent surgery; vascular clips; metal implants or joint replacements; have had metal fragments in their eyes; has ever worked on a lathe; has shrapnel from a war injury Known allergy e.g. seafood, hayfever, hives Pregnant or breastfeeding women Male or pre-menopausal female participants of child-bearing potential* unwilling to use an effective method of birth control (either hormonal in the form of the contraceptive pill or barrier method of birth control accompanied by the use of a proprietary spermicidal foam/gel or film ; or agreement of true abstinence (i.e. withdrawal, calendar, ovulation, symptothermal and post ovulation are not acceptable methods) from time consent is signed until 6 weeks after the last dose of IMP Enrolled on another CTIMP study Intercurrent use of any medication known to be contraindicated in Brugada Syndrome Any contraindication to ajmaline Provocation as detailed in the approved St George’s Hospital clinical ajmaline protocol. *Subjects are only considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The aim of this study is to observe the participants electrocardiographic response to Ajmaline and analyse this response qualitatively and quantitatively.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Immediate analysis of the electrocardiographic response will take place. |
|
E.5.2 | Secondary end point(s) |
An association between both resting and provocation ECG and cardiac structural variations seen on cardiac magnetic resonance imaging (MRI).
An association between genomic variations and both resting and provocation ECG phenotypes
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The assessment for structural and genetic variation will take place alongside the active part of the study. Any overall association between the variables and the outcome will be assessed once the entire cohort has been investigated. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 1 |